HEMATOLOGIC MALIGNANCIES
Clinical trials for HEMATOLOGIC MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGIC MALIGNANCIES trials appear
Sign up with your email to follow new studies for HEMATOLOGIC MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat myeloma: teclistamab trial in japan
Disease control CompletedThis study tested teclistamab, a drug that helps the immune system find and attack myeloma cells, in 40 Japanese patients whose multiple myeloma had returned or stopped responding to treatment. The goal was to check safety and find the right dose in phase 1, then see how well it …
Matched conditions: HEMATOLOGIC MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo may make cord blood transplants safer for blood cancer patients
Disease control CompletedThis study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…
Matched conditions: HEMATOLOGIC MALIGNANCIES
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Blood cancer drug safety checked in small Follow-Up study
Disease control CompletedThis study looked at the long-term safety of an oral chemotherapy drug (azacitidine) in 5 adults with blood cancers who had already taken it in earlier studies. Researchers tracked side effects and survival to see if continued treatment was safe. The goal was to monitor risks, no…
Matched conditions: HEMATOLOGIC MALIGNANCIES
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New cocktail targets tough lymphomas
Disease control CompletedThis early-phase study tested a combination of three drugs (VIP152, venetoclax, and prednisone) in 8 adults with aggressive non-Hodgkin lymphomas that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose, while also measuri…
Matched conditions: HEMATOLOGIC MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Bone marrow transplant breakthrough: more donors now possible for blood cancer patients?
Disease control CompletedThis study tested a gentler bone marrow transplant for people with blood cancers who don't have a perfectly matched family donor. Instead, it used donors who are less closely matched, like unrelated volunteers or distant relatives. The goal was to see if this approach could be sa…
Matched conditions: HEMATOLOGIC MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New Blood-Cleansing method boosts transplant success in High-Risk patients
Disease control CompletedThis study looked at 50 patients who needed a stem cell transplant from a partially matched donor but had antibodies that could attack the donor cells. Before transplant, they received a blood purification treatment called protein A immunoadsorption to remove those antibodies, so…
Matched conditions: HEMATOLOGIC MALIGNANCIES
Sponsor: Ting YANG • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug shows promise in preventing transplant complications
Disease control CompletedThis study tested whether the drug tildrakizumab could help prevent graft-versus-host disease (GVHD) in 51 adults receiving a stem cell transplant for blood cancers. GVHD is a serious complication where donor cells attack the patient's body. The goal was to see if adding tildraki…
Matched conditions: HEMATOLOGIC MALIGNANCIES
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Blood test may spot deadly transplant complication earlier
Diagnosis CompletedThis completed study looked at whether certain proteins in the blood (called biomarkers) can help predict acute graft-versus-host disease (aGVHD) in 500 patients who had a stem cell transplant for blood cancers. Researchers measured levels of REG3, ST2, IL-6, IL-8, and TNF R ever…
Matched conditions: HEMATOLOGIC MALIGNANCIES
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
Fencing fights fatigue: new program aims to keep blood cancer patients moving
Symptom relief CompletedThis study tested whether a fencing-based exercise program is practical for adults with leukemia or lymphoma who are receiving intensive treatment in a hospital. The goal was to reduce physical decline caused by long bed rest. Eighty patients were invited to take part, and resear…
Matched conditions: HEMATOLOGIC MALIGNANCIES
Phase: NA • Sponsor: University Hospital, Angers • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
Hospital program helps older blood cancer patients plan future care
Knowledge-focused CompletedThis study tested a program to help older patients (age 60+) with blood cancers plan their future medical care while in the hospital. The program focused on completing advance directives and healthcare proxy forms. Out of 41 participants, the study found that the program was feas…
Matched conditions: HEMATOLOGIC MALIGNANCIES
Phase: NA • Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
COVID-19's hidden toll: fungal infections rise in transplant patients
Knowledge-focused CompletedThis study looked back at 60 adult blood cancer patients who had stem cell transplants and later developed a rare fungal infection called mucormycosis. Researchers compared cases before COVID-19 (2015-2020) to during the pandemic (2020-2024) to see if the virus, new tests, or new…
Matched conditions: HEMATOLOGIC MALIGNANCIES
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC